Market research
HEM.V Hemostemix Inc
V CAD Healthcare
Latest close
As of 29 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 13M
- P/E ratio
- Not available
- Analyst target
- 0.96
- Dividend yield
- Not available
- Beta
- 0.73
Profile
Instrument facts
- Exchange
- V
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- CA4236943060
- Market cap
- 13M
- P/E ratio
- Not available
- Analyst target
- 0.96
- Dividend yield
- Not available
- Beta
- 0.73
About
About Hemostemix Inc
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which completed Phase II clinical trial for the treatment of peripheral arterial disease, chronic limb threatening ischemia, cardiovascular ischemia and angina, and vascular dementia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.
Research context
Hemostemix Inc appears in PyInvesting’s TSX Venture Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the HEM.V discussion.
5 years, 6 months ago
Hemostemix Inc is currently in a long term downtrend where the price is trading 16.6% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Hemostemix Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 18.5% to $-2M since the same quarter in the previous year.
Finally, its free cash flow grew by 60.1% to $-514K since the same quarter in the previous year.
Based on the above factors, Hemostemix Inc gets an overall score of 2/5.